Conditions for immunosuppression by rifampicin.
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects*; D000921:Antibody-Producing Cells; D022121:Cholera Vaccines; D004912:Erythrocytes / Q000276:immunology; D004926:Escherichia coli / Q000276:immunology*; D006462:Hemolytic Plaque Technique; D006801:Humans; D007165:Immunosuppression Therapy; D008070:Lipopolysaccharides; D008264:Macrophages / Q000187:drug effects; D051379:Mice; D010587:Phagocytosis / Q000187:drug effects; D011135:Polysaccharides, Bacterial; D012293:Rifampin / Q000494:pharmacology* / Q000633:toxicity; D012756:Sheep / Q000276:immunology
D022121:Cholera Vaccines; D008070:Lipopolysaccharides; D011135:Polysaccharides, Bacterial; D012293:Rifampin